Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies.

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Anti-amyloid therapies represent a significant advancement in Alzheimer's disease (AD) treatment.
• These drugs aim to reduce amyloid plaque burden in the brain.
• Observed clinical benefits are modest, and concerns exist regarding long-term efficacy and safety.

Purpose of the Study:

• To investigate the mechanisms behind paradoxical acceleration of brain volume changes associated with anti-amyloid drugs.
• To evaluate the implications of these volume changes on the sustained benefit of Alzheimer's disease therapies.
• To advocate for the transparent release of clinical trial data for comprehensive analysis.

Main Methods:

• Review of existing clinical trial data and imaging studies related to anti-amyloid therapies.
• Analysis of neuroimaging biomarkers, including brain volume measurements.
• Examination of potential biological explanations for accelerated brain volume changes.

Main Results:

• Anti-amyloid drugs demonstrate a modest effect in slowing Alzheimer's disease progression.
• A concerning trend of paradoxical acceleration in brain volume changes was observed in patients treated with these drugs.
• The long-term clinical significance and underlying causes of these volume changes remain uncertain.

Conclusions:

• While anti-amyloid drugs offer some benefit, their sustained efficacy is questionable due to effects on brain volume.
• Understanding the reasons for accelerated brain volume changes is critical for optimizing Alzheimer's disease treatment.
• Transparent sharing of clinical trial data is essential for robust scientific evaluation and improved patient outcomes.